CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

China

Guangzhou Medical University Affiliated Women and Children's Medical Center, Guangzhou, Guangdong